Ekaphop Sirachainan

270 Rama VI Road
Ratchathewi, 10400, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Gut microbiome in advanced non-small cell lung cancer: effect of chemotherapy and impact on efficacy.

Gut microbiome in advanced non-small cell lung cancer: effect of chemotherapy and impact on efficacy.

Journal: Translational lung cancer research

Published: February 19, 2026

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.

Journal: BMJ oncology

Published: January 24, 2026

Dynamics of the immune repertoire in recurrent, locally advanced NSCLC not amenable for definitive therapy and in stage IV disease receiving first-line chemotherapy.

Dynamics of the immune repertoire in recurrent, locally advanced NSCLC not amenable for definitive therapy and in stage IV disease receiving first-line chemotherapy.

Journal: Frontiers in oncology

Published: January 14, 2026

Association between miRNA expression profiles and polymorphisms of dihydropyrimidine dehydrogenase drug-metabolizing gene in patients with colorectal cancer receiving 5-fluorouracil.

Association between miRNA expression profiles and polymorphisms of dihydropyrimidine dehydrogenase drug-metabolizing gene in patients with colorectal cancer receiving 5-fluorouracil.

Journal: Biomedical reports

Published: May 20, 2025

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study.

FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 12, 2025

The impact of systemic inflammatory markers on EGFR-mutant non-small cell lung cancer.

The impact of systemic inflammatory markers on EGFR-mutant non-small cell lung cancer.

Journal: BMC cancer

Published: April 12, 2025

Biosimilars in practice: Discriminant factors influencing prescription decisions among physicians in Thailand.

Biosimilars in practice: Discriminant factors influencing prescription decisions among physicians in Thailand.

Journal: PloS one

Published: January 27, 2025

Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients.

Influence of DPYD gene polymorphisms on 5-Fluorouracil toxicities in Thai colorectal cancer patients.

Journal: Cancer chemotherapy and pharmacology

Published: July 27, 2024

APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.

APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.

Journal: Hepatology international

Published: July 11, 2024

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 27, 2023

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.

Journal: ESMO open

Published: November 08, 2023

Dynamic changes in immune repertoire profiles in patients with stage III unresectable non-small cell lung cancer during consolidation treatment with immunotherapy.

Dynamic changes in immune repertoire profiles in patients with stage III unresectable non-small cell lung cancer during consolidation treatment with immunotherapy.

Journal: BMC cancer

Published: September 05, 2023

Showing 1-12 of 39

Last Updated: 09/26/2026